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Hong-Jin Shu2, Charles F. Zorumski2 and Steven Mennerick2*
1 Sage Therapeutics, Cambridge, MA, United States, 2 Department of Psychiatry, Taylor Family Institute for Innovative
Psychiatric Research, Washington University, University School of Medicine in St. Louis, St. Louis, MO, United States
The manipulation of cholesterol and its metabolites has been hypothesized to
be therapeutically beneficial for mood disorders, neurodegenerative disorders, and
epilepsies. A major regulator of cholesterol clearance and turnover in the central
nervous system is CYP46A1, a brain enriched enzyme responsible for metabolism
of cholesterol into 24S-hydroxycholesterol. Inhibition of this enzyme may negatively
modulate NMDARs as 24S-hydroxycholesterol was shown to enhance NMDAR
function. In addition, alterations of local cholesterol or other changes mediated by
CYP46A1 activity could have important influences on central nervous system function.
Here we demonstrate that humans and mice display brain region specific and similar
CYP46A1 and 24S-hydroxycholesterol distribution. Treatment with distinct classes of
CYP46A1 inhibitors led to central 24S-hydroxycholesterol reduction in vivo and ablation
of long term depression in hippocampal slices. Our results suggest that rodents show
similarity to humans for studying the impact of CYP46A1 inhibitors and that rapid, local
modulation of oxysterols can be achieved through CYP46A1 inhibition.
Keywords: CYP46A1, 24S-hydroxycholesterol, cholesterol, LTD, NMDAR
INTRODUCTION
The oxysterol 24S-hydroxycholesterol (24S-HC) is an enzymatically generated oxidation product of
cholesterol. It is selectively synthesized in central nervous system (CNS) neurons by the cytochrome
P450 enzyme cholesterol 24-hydroxylase (CYP46A1). Although 24S-HC flux to the periphery is
important for brain cholesterol turnover (Russell et al., 2009), signaling roles for 24S-HC and
therapeutic interventions targeting 24S-HC in the CNS have also been suggested (Alves et al., 2016;
Sun et al., 2016b; Bialer et al., 2018; Petrov and Pikuleva, 2019). Better understanding of the roles
of 24S-HC requires knowledge of regional variation in CYP46A1 and 24S-HC levels, as well as how
manipulations of 24S-HC levels impact brain function.
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The brain synthesizes its own cholesterol, as lipoprotein-
bound cholesterol does not pass the blood-brain barrier. The
neuronal cholesterol pool is labile and turns over regularly,
primarily by conversion to 24S-HC, which passes the blood-
brain barrier for elimination in the liver (Russell et al., 2009).
Interestingly, constitutive loss of CYP46A1 does not result in
changes to cholesterol concentrations or in other oxysterols
(Meljon et al., 2014). This implies complex regulatory and
feedback mechanisms to maintain cholesterol homeostasis.
However, acute changes to CYP46A1 function alter cholesterol
and 24S-HC levels (Sodero et al., 2012; Djelti et al., 2015; Bialer
et al., 2018; Kacher et al., 2019), which could have an impact on
brain physiology.
It has been shown that many cholesterol metabolites,
including oxysterols, have CNS signaling roles (Paul et al., 2013;
Sun et al., 2017). 24S-HC appears to be no exception. It alters
transcription by binding liver X receptors (Gabbi et al., 2014),
and modulates ion channel function such as the N-methyl-
D-aspartate receptor (NMDAR) (Paul et al., 2013). 24S-HC
elevation may have a therapeutic effect in neurodegenerative
conditions where decreased levels of CYP46A1 enzyme have
been reported (Alves et al., 2016), but inhibition of CYP46A1
may be beneficial in diseases accompanied by increased levels
of 24S-HC, such as hypoxia (Lu et al., 2020), conditions that
promote excessive excitation, which are associated with increased
CYP46A1 activity (Sodero et al., 2012). Regional variability in
24S-HC levels may yield insight into the impact of 24S-HC on
brain function and behavior, but little work has been done to
evaluate this notion (Yutuc et al., 2019, 2020).
Here we evaluated regional expression and distribution of
CYP46A1 and 24S-HC in mouse and compared it to published
data from human brain. We followed up by characterizing known
structurally distinct CYP46A1 inhibitors. We find selective
actions of these compounds ex vivo and in vivo which we
attribute to CYP46A1 inhibition as they have no demonstrable
binding at a number of other potential protein targets.
Systemic administration of these compounds achieved good
brain exposure and reduced 24S-HC. However, administration
of inhibitors for up to 6 h to hippocampal tissue slices did not
appreciably alter 24S-HC levels but altered long-term synaptic
plasticity, suggesting that local actions of 24S-HC may be
important for NMDAR mediated function. Our results help
establish a more comprehensive picture of potential therapeutic
applications of 24S-HC synthesis pathways.
MATERIALS AND METHODS
Compound Supply
Structurally distinct CYP46A1 inhibitors, compound
1 ((3-oxa-8-azabicyclo[3.2.1]octan-8-yl)(8-(oxazol-5-yl)-6-
(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)methanone (Kamal
et al., 2015) and compound 2 ((4-(4-fluorobenzyl)-
4-hydroxypiperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-
yl)methanone, were identified (Figure 3A) and synthesized.
Voriconazole (Bioscience, Ellisville MO), ketamine
hydrochloride injectable (Gutian pharmaceutical Co. Ltd.,
Fujian), hydroxypropylmethyl-cellulose (MC; Sigma-Aldrich,
St. Louis, MO, United States; CAS#9004-65-3) and sterile
saline (Shan Dong Hualu Pharmaceutical, Shan Dong, China)
were purchased.
Data Mining From the GTEx Portal
Human sample collection and analysis for mRNA quantification
by the GTEx portal has previously been described (Lonsdale
et al., 2013). The mean number of subjects examined for
CYP46A1 expression within samples presented was 317 with the
maximum examined in muscle from 803 subjects and minimum
in kidney from 4 subjects. Within the brain, the lowest number
of samples was collected from substantia nigra where 139
subjects were examined.
Western Blot
Proteins were isolated from mouse brain tissue with RIPA
lysis buffer containing 150 mM sodium chloride, 1% Triton
X-100, 0.5% sodium deoxycholate, 2.5 mM EDTA, 0.1% SDS,
and 50 mM Tris-HCl, pH 8, with protease inhibitor cocktail
(MilliporeSigma, St. Louis, MO). Homogenates were centrifuged
at 15,000 rpm at 4◦C for 20 min. The clear supernatant was
stored at −70◦C. Protein concentrations within each homogenate
were determined with the Pierce Coomassie protein assay reagent
(Micro BCA, Thermo Fisher Scientific, Waltham, MA). A 25
µg protein sample was run on 4–15% polyacrylamide gel (Bio-
Rad Laboratories, Hercules, CA) at 100 V for 1 h. Proteins
and molecular weight markers (Lamda Biotech Corp., St. Louis,
MO) were transferred by electrophoresis onto an Immunobilon-
P membrane (MilliporeSigma, St. Louis, MO) at 4◦C and
processed for immunodetection. Incubation of the membrane
with blocking solution (3% non-fat milk in PBS for 1 h at RT)
was followed with incubation in primary antibody (Rabbit anti
CYP46A1, #SAB-1410134; MilliporeSigma) at 1 µg/mL dilution
in blocking solution at 4◦C overnight and washed three times.
The membrane was next incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG secondary antibody (Santa Cruz
Biotechnology, Dallas, TX) 1:2,000 dilution for 2 h. A Lumigen
ECL Ultra kit was used for detection. Bands were digitized
on a Kodak ImageStation 440CF. The intensity of bands was
quantitated with ImageJ software (NIH). After image capture,
blots were stripped using Restore Western blot Stripping Buffer
(Thermo Fisher Scientific) and reprobed with tubulin antibody
(MilliporeSigma) as an internal control for sample loading.
CYP46A1 Enzyme Assay With
Testosterone as Substrate
In 96-well plate format, 88.5 µL of human CYP46A1R
bactosomes (50 pM/mL final concentration; Cypex, Catalog
Number CYP068) in potassium phosphate buffer with MgCl2 and
1 µL of varying half-log concentrations of inhibitor or a standard
curve of 16β-hydroxytestosterone were added to designated wells
and incubated at 37◦C for 2 min. The substrate testosterone (0.5
µL of a 3,000 µM solution) and 10 µL of the NADPH generating
system were added to all wells and incubated for 10 min at
37◦C. The reaction was stopped by adding 100 µL of methanol
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containing 1 µM of the internal standards bucetin and diclofenac.
The plates were sealed and placed in a −20◦C freezer for 10 min,
centrifuged at 5,700 rpm for 20 min at 4◦C and the supernatants
transferred for LC-MS/MS analysis.
The NADPH generating system was prepared by
combining 1,500 µL of 200 mM glucose-6-phospate, 3,000
µL of 20 mM NADH, 60 µL of 1,000 U/mL glucose-6-
phosphate dehydrogenase and 1,440 µL of 100 mM potassium
phosphate at pH 7.4.
16β-Hydroxytestosterone LC-MS
Analysis
Samples were injected onto a Waters Acquity UPLC with an
Acquity UPLC HSS T3 1.8 µm, 2.1 × 50 mm column and triple
quadrupole Xevo TQ MS detector using a gradient elution using
mobile phase A of water with 0.1% formic acid and mobile
phase B of acetonitrile with 0.1% formic acid. The gradient was
maintained at 2% B for 0.05 min, then ramped linearly to 95%
B in 0.95 min, then immediately returned linearly to 2% B in
0.50 min with a total runtime of 1.8 min. The reaction product
16β-hydroxytestosterone was monitored (parent m/z 305.1844
and daughter m/z 96.9690) and quantified. Dose response curves
were generated by graphing 16β-hydroxytestosterone levels vs.
inhibitor concentrations.
CYP46A1 Cholesterol Assay
In 384-well plate format, 0.5 µL of human CYP46A1 microsomes
(25mg/mL, Premas Biotech, Gurugram, India) were incubated
for 5 min with 2-hydroxypropyl-β-cyclodextrin (10 mg/mL)
and 100 mM potassium phosphate buffer (pH 7.4) containing
5 mM MgCl2. 1 µL of varying half-log concentrations of
inhibitor were added to designated wells and incubated for
5 min. Cholesterol (25 µM) was then added and the reaction
was initiated using 1 mM NADPH. The reaction was conducted
at 37◦C for 30 min in a total incubation volume of 50 µL.
After the incubation 30 µL of incubation mixture was added
to a pre-made quench plate containing 30 µL 1 µM d7-24
hydroxy cholesterol in acetonitrile/methanol (50/50) to terminate
the reaction. Subsequently, the plates were sealed and placed in
a −20◦C freezer for 10 min, centrifuged at 5,700 rpm for 20 min
at 4◦C and the supernatants transferred for LC-MS/MS analysis.
24-Hydroxycholesterol LC-MS Analysis
Samples were injected onto a SCIEX 6500 QTRAP Mass
Spectrometer with an Eclipse XDB-C18 (3 × 100 mm, 3.5
µm) column using a gradient elution using mobile phase
A of water with 0.1% formic acid and mobile phase B of
methanol:acetonitrile (50:50, v:v) at a flow rate of 600 µL/min at
50◦C. The gradient was maintained at 80% B for 0.01 min, then
ramped linearly to 100% B in 3 min, then returned linearly after
3.3 min to 80% B in 4.30 min with a total runtime of 11 min. The
reaction product 24-hydroxycholesterol was monitored (parent
m/z 385.0 and daughter m/z 367.0) and quantified in comparison
to d7-24-hydroxycholesterol standard. Dose response curves
were generated by graphing 24-hydroxycholesterol levels vs.
inhibitor concentrations.
Analytical Method for 24S-HC Quantification in
Mouse Plasma, Brain, and Brain Slices
Male CD1 mice (Vital River, Beijing, China) were housed
in plastic cages with metal covers (GAU-2, Suzhou Fengshi
Laboratory animal equipment Co., LTD, Suzhou, China) in
groups of 5 under controlled conditions (temperature of
20−26◦C and 12:12 light-dark cycle, lights on at 5:00 am) with
a standard rodent diet and water available ad libitum. The mice
were acclimated for 5 days under these conditions before testing.
The animals were randomly assigned to experimental groups;
each mouse was used only once. At the time of the experiment
mice were 5–6 weeks old. The experiment was approved by
the Institutional Animal Care and Use Committee of Shanghai
ChemPartner Co., Ltd.
Under the assay conditions, both 24S and 24R-
hydroxycholesterol were detected in a single peak and quantified
as total 24-hydroxycholesterol. Total 24-HC was measured using
ester hydrolysis, liquid-liquid extraction, and measurement
by LC-MS/MS. Brain or plasma samples were first diluted
with PBS at a ratio of 3 mL of PBS to 1 g of tissue. Tissue
homogenate was prepared using a bead mill type homogenizer
(Spex-certiprep Genogrinder).
The 50 µL sample with 5 µL of 24-hydroxycholesterol-d6
internal standard was added to 100 µL of 0.35 N KOH in
methanol and heated to 80◦C for 2 h. Hydrolyzed plasma or
tissue homogenate (155 µL) was mixed with 200 µL of DI water
and extracted with 1 mL of methyl-t-butyl ether. The organic
layer was separated and taken to dryness under nitrogen at 50◦C.
The dry residue was reconstituted in 100 µL of 80% methanol
in DI water. Reconstituted sample (5 µL) was injected on an
ACE 3C18 0.5 mm × 1.0 mm HPLC column. Gradient elution
was performed using an Eksigent LC200 HPLC system running
a simple water:acetonitrile gradient from 70% acetonitrile to 95%
acetonitrile over 4.75 min at a flow rate of 100 µL/min.
Calibrators and assay quality controls were made by spiking
24S-hydroxycholesterol-d7 into control mouse plasma or brain
homogenate and preparing them as samples. Detection of
24S-HC was accomplished using a Sciex Qtrap 5500 mass
spectrometer running selected reaction monitoring of the analyte
and internal standard. Ions were formed using a TurboV
electrospray ion source operated in the positive ion mode. Sample
concentrations were determined using the peak area ratio of
analyte to internal standard and the least squares linear regression
equation from the standard curve.
Assay acceptance criteria for each LC-MS/MS run were ±20%
accuracy compared to the nominal spiked concentration and
±20% CV. Endogenous quality controls made from control
plasma or brain tissue were used to track longitudinal assay
performance. Endogenous quality controls must reproduce
within 3 SDs of the latest 20 measurements.
Hippocampal Slice Physiology
Protocols for animal use in ex vivo studies were approved
by the Washington University Institutional Animal Care and
Use Committee in accordance with international guidelines.
Hippocampal slices were freshly prepared from the dorsal
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hippocampal region of postnatal day (P) 30–34 Harlan Sprague-
Dawley male albino rats or C57Bl/6 mice (Tokuda et al., 2010).
CYP46A1 mice were on the C57B/6 background as described
previously (Sun et al., 2016a). Rodents were anesthetized with
isoflurane, decapitated, and hippocampi were dissected. Isolated
hippocampi were placed in ice-cold artificial cerebrospinal fluid
(ACSF) containing (in mM): 124 NaCl, 5 KCl, 2 MgSO4, 2 CaCl2,
1.25 NaH2PO4, 22 NaHCO3, 10 glucose, bubbled with 95% O2-
5% CO2 at 4−6◦C, and cut into 450 µm slices using a rotary
tissue slicer. Following dissection, slices were allowed to recover
in an incubation chamber containing gassed ACSF for 1 h at 30◦C
before experiments.
At the time of study, slices were transferred individually to
a submersion-recording chamber that was maintained at 30◦C
with continuous ACSF perfusion at 2 mL/min. Extracellular
recordings were obtained from stratum radiatum of the CA1
region for analysis of excitatory postsynaptic potentials (EPSPs)
using glass electrodes filled with 2 M NaCl (5–10 M resistance).
EPSPs were evoked using 0.1 ms constant current pulses
through a bipolar stimulating electrode in the Schaffer
collateral (SC) pathway. Responses were monitored throughout
experiments using single stimuli every 60 s at half maximal
intensity based on a control input-output (IO) analysis. After
establishing a stable baseline for at least 10 min, long-term
depression (LTD) was induced using 1 Hz low frequency
stimulation (LFS) for 15 min (900 pulses), a stimulation protocol
that reliably induces NMDAR-dependent LTD (Izumi and
Zorumski, 2012). IO curves were repeated 60 min following LFS.
Statistical Analysis
All data presented as mean ± S.E.M. Graphpad Prism 8.0
was used for all data analyses. A one-way ANOVA followed
by Dunnett’s test was used for analysis of CYP46A1 protein
expression (Figure 2B) and 24S-HC levels (Figure 2C) in the
mouse brain regions. Indicated where multiple comparison
significance (p < 0.05 or better) between experimental variables.
A two-way ANOVA with multiple comparison was used for
assessment of compound 1 on 24S-HC at indicated timepoints
(Figure 4). A two-way ANOVA (dose and time as between
factors) evaluated the time course of compound 1 compared
to vehicle across the selected time points (Figure 6). After a
significant interaction between dose and time was identified, a
Sidak’s multiple comparison test was used to evaluate vehicle vs.
compound 1 at each timepoint. Measurements from two female
mice did not obviously differ from those of males, so we did not
pursue sex differences further (Supplementary Figure 1).
Electrophysiogical data were collected and analyzed using
PClamp software (Axon Instruments, Union City CA). Data
in the text are expressed as mean ± SEM. A two-tailed
Student’s t-test was used for comparisons between groups with
correction for multiple comparisons when appropriate. Statistical
comparisons were based on data from IO curves at baseline and
60 min following LFS with p < 0.05 considered significant. The
graphs in all figures display results from continuous monitoring
of synaptic responses at very low frequency during the course
of experiments, while results presented in the text and statistical
comparisons are derived from analysis of IO curves as noted
above. Statistical analyses were done using commercial software
(SigmaStat, Systat Software, Inc., Richmond City, CA).
RESULTS
CYP46A1 Expression Within Human and
Rodent Brains
Human CYP46A1 expression, based on RNA-seq quantification,
is preferentially expressed within the central nervous system,
where transcripts are in excess of 100 per million while in most
of the peripheral tissues they are less then 5 transcripts per
million (Figure 1). The only notable exception is the pituitary
gland where CYP46A1 message can be as high as 25 transcripts
per million (Figure 1B). Within the brain, CYP46A1 exhibits
differential tissue expression as its distribution is highest within
the striatum (caudate, putamen and nucleus accumbens), cortex
(cortex, frontal cortex and anterior cingulate cortex), amygdala,
hippocampus and cerebellum (Figure 1A). Human RNA-seq data
were mined from the GTEx Portal.
In mouse, we used an antibody to quantify CYP46A1 protein
expression. Similar to human, mouse CYP46A1 distribution
displays brain region specific expression. CYP46A1 antibody
was first confirmed to be immunoreactive against whole brain
lysates from wildtype, but not CYP46A1 knockout mice, on
western blot (Figure 2A), reinforcing its selectivity for CYP46A1
detection. This antibody was subsequently used to quantify
CYP46A1 protein expression across several mouse brain regions,
including the striatum, hippocampus, cortex, and cerebellum
(Figure 2B). We found this CYP46A1 antibody not to be suitable
for immunohistochemistry staining, as judged by staining
in postnatal day 70–90 knockout tissue (Sun et al., 2016a)
under several different fixation and permeabilization protocols
(Supplementary Figure 2). Other antibodies have been used
previously for immunostaining (Ramirez et al., 2008), but in
our hands the 1A7 antibody used in this work (MilliporeSigma)
yielded multiple bands in western blots, so we did not pursue it.
Since the presumed function of the CYP46A1 enzyme is to
catalyze synthesis of 24S-HC (Mast et al., 2004) we also quantified
this product across several mouse brain regions. 24S-HC was
highest in the striatum and lowest in the cerebellum (Figure 2C)
which reflected CYP46A1 expression levels. The cortical 24S-
HC level was similar to that of the striatum and higher than
expected based on CYP46A1 protein expression, suggesting
different rates of synthesis or retention of this oxysterol. Mouse
gender did not have an obvious impact on the level of 24S-HC
(Supplementary Figure 1).
In vitro and in vivo Pharmacology of
CYP46A1 Inhibitors
Compounds 1 and 2 represent examples of two distinct
structural classes of CYP46A1 inhibitors identified recently
(Figure 3A). These examples have been of interest as tool
compounds in commercial development (indicated by patent
numbers in Figure 3). Both representatives completely inhibit
the oxidation of testosterone to 16-beta-hydroxytestosterone by
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FIGURE 1 | Human CYP46A1 expression, from RNA-seq analysis. CYP46A1 mRNA is predominantly expressed within the brain (A) but not in the periphery (B).
Brain expression is highest in the striatum > cortex > hippocampus > cerebellum. Box plots are shown as median with 25th and 75th percentiles. TPM, transcripts
per million. Data mined from GTEx portal (Lonsdale et al., 2013). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office
of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this figure were
obtained from the GTEx Portal on July 16th of 2019.
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FIGURE 2 | Mouse brain CYP46A1 and 24S-HC expression. CYP46A1 antibody was validated on whole brain lysate from CYP46A1 KO mice (A). Topographically
distinct CYP46A1 rodent brain expression observed with highest expression in the striatum > hippocampus > cortex/cerebellum. Representative lanes from western
blots are shown. (B) Brain region 24S-HC differential observed with highest 24S-HC detected in striatum/cortex > hippocampus > cerebellum (C). *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.
FIGURE 3 | In vitro profile of CYP46A1 inhibitors. Compounds 1 and 2 are examples of chemically distinct (A) and potent inhibitor classes that completely inhibit
CYP46A1 when used with testosterone (B) or cholesterol as substrates (C). The numbers beneath the compounds indicate patent numbers.
human CYP46A1 enzyme in vitro with IC50s of 26 and 37
nM, respectively (Figure 3B). In vitro potency of voriconazole
using testosterone as a substrate was found to be 35.9 µM
(Figure 3B). Initially, testosterone was utilized as substrate in
this reaction owing to its improved solubility over cholesterol,
enabling better run to run reproducibility (Mast et al., 2003).
We also developed an in vitro assay using cholesterol as a
substrate. Both compounds 1 and 2 completely inhibit the
conversion of cholesterol to 24-hydroxycholesterol by human
CYP46A1 enzyme in vitro with IC50s of 22 nM and 32 nM
(Figure 3C), comparable to the potency using testosterone as
substrate (Figure 3B). The IC50 of voriconazole in the cholesterol
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assay was 12.2 µM (Figure 3C). Both compounds 1 and 2 were
found to be free of off-target pharmacology as demonstrated
by lack of meaningful effect against a series of 69 receptor
and enzyme targets with in a CEREP panel (Supplementary
Table 1), 7 CYP enzymes (Supplementary Table 2) and 97
kinases (Supplementary Table 3).
In an attempt to further elucidate the properties of these
CYP46A1 inhibitors, we were curious to see if we could decrease
24S-HC levels in brain slices after acute administration of
CYP46A1 inhibitors. Application of either of the two CYP46A1
inhibitors to mouse striatal and hippocampal slices for 0.5,
2, or 6 h did not influence bulk 24S-HC levels within those
slices relative to vehicle treatment (Figure 4). Possibilities for
the lack of an effect could be due to low aqueous solubility
of 24S-HC preventing washout of existing hydroxycholesterol,
insufficient time of CYP46A1 inhibition or a species difference,
which would preclude these inhibitors from working on the
mouse CYP46A1 enzyme.
To help understand these possibilities, we turned to
NMDAR-dependent forms of synaptic plasticity. In postnatal
day 30 CYP46A1−/− mice, we previously found no deficit
in hippocampal CA1 LTP (Sun et al., 2016a). Rather, a
significant LTD deficit in hippocampal slices from CYP46A1
knockout mice was observed (p = 0.049) (Figure 5A), and
we previously showed that synaptic depression triggered
by oxygen-glucose deprivation is dependent on CYP46A1
(Sun et al., 2016a). Voriconazole, a previously characterized
pharmacological inhibitor of CYP46A1 (Shafaati et al., 2010;
Mast et al., 2013), also depressed LTD (p = 0.0027) in a 24S-
HC sensitive manner (p = 0.006) (Figure 5B). The emerging
picture was somewhat more complicated with the newer
CYP46A1 inhibitors examined here. Both compounds inhibited
LTD (p = 0.0039 and 0.0014, respectively). However, 24S-HC
overcame the LTD deficit induced by compound 1 (p = 0.046)
(Figure 5C) but failed to reverse the LTD deficit induced
by compound 2 (p = 0.144) (Figure 5D). Pharmacologically
isolated NMDA receptor-mediated EPSPs were unaffected by
compounds 1 and 2, and by voriconazole at concentrations
that inhibited LTD (Supplementary Figure 3). Potential reasons
for the differing behavior of the compounds are treated
in the Discussion.
Single oral administration of compound 1 to mice led to
peripheral and central exposure in excess of the in vitro CYP46A1
IC50 for at least 4 h (Figure 6A). Since we observed sufficient
exposure of compound 1 to suggest engagement of CYP46A1,
we quantified the impact of acute treatment on plasma and
brain 24S-HC within 16 h of treatment. While vehicle treated
plasma 24S-HC underwent some changes during the time of
the experiment, perhaps suggesting a level of experimental
variability, a statistically significant plasma 24S-HC decrease
was observed 8 h post compound 1 treatment (Figure 6B).
A statistically significant decrease in brain 24S-HC was also
observed after CYP46A1 inhibitor administration at 4, 8, and 16 h
(Figure 6C) demonstrating that inhibition of CYP46A1 in vivo
results in decreased 24S-HC levels in both brain and plasma
within a relatively short timeframe.
Next, we utilized a subchronic paradigm, consisting of 3 days
of BID dosing, to test if further 24S-HC reductions could be
observed with a longer duration of CYP46A1 inhibition. We
also tested if compound 2 would likewise lead to similar 24S-HC
reductions. Longer exposure of the two compounds, at the same
dose as in the acute study (Figures 6D,G), resulted in significantly
larger plasma (Figures 6E,H) and brain (Figures 6F,I) 24S-HC
reduction than with the acute treatment.
Plasma 24S-HC levels are about the same level, reaching about
40 ng/mL, in mice from the three vehicle treated experiments
(Figures 6B,E,H). However, vehicle treated brain 24S-HC levels
display considerable variability at 40, 13, and 29 µg/g in the three
experiments (Figures 6C,F,I), respectively. This variability may
be attributed to the nature of the matrix, and its propensity for
endogenous interferences in tissue bioanalysis. Brain is a fatty
tissue enriched in endogenous lipophilic components, presenting
challenges in extracting out the similarly lipophilic 24S-HC
analyte from other cholesterol-like molecules. Matched vehicle
controls were used in every experiment to accurately assess
magnitude of treatment mediated 24S-HC changes to control for
inter-assay variability. Further work may be needed to lessen the
variability and improve the extraction analytics.
FIGURE 4 | No impact of CYP46A1 inhibitor treatment on striatal (A) or hippocampal (B) slice 24S-HC levels. The number of independent tissue slices from three
different animals is given. Tissue harvest followed by rapid freezing occurred at the indicated times.
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FIGURE 5 | The impact of various inhibitors of CYP46A1 on long-term depression in hippocampal slices. (A) Constitutive deletion of cyp46a1 in mice results in loss
of LTD. Exogenous application of 24S-HC (10 µM) restores LTD. For WT, LTD as a percentage of baseline efficacy was 71.1 ± 7.3%, N = 8; KO: 94.7 ± 8.3%,
N = 9, p = 0.049. 24S-HC: 54.6 ± 8.4%, N = 5, p = 0.007 vs. KO without 24S-HC. Sample traces for this and subsequent panels show baseline (solid) and
post-LFS (dashed) examples, color-coded as in the time plot. (B) Voriconazole (3 µM) reduces LTD vs. vehicle controls (p = 0.0027), and 10 µM 24S-HC restores
LTD in rat slices. LTD was 104.9 ± 5.3%, N = 5 in the presence 3 µM voriconazole alone and 53.8 ± 12.4% (N = 5) with pretreatment with 24S-HC (10 µM),
p = 0.006. (C,D) Compound 1 (10 µM; 97.9 ± 7.7%, N = 5, p = 0.0039 vs. vehicle controls) and compound 2 (1 µM; 129.0 ± 13.4%, N = 7, p = 0.0014 vs. vehicle)
reduce LTD; 10 µM 24S-HC restores LTD only for compound 1 (10 µM; 66.8 ± 10.4%, N = 6, p = 0.046; for 24S-HC + compound 2 105.5 ± 6.7%, N = 7,
p = 0.144). Concentrations of compounds 1 and 2 were chosen based on threshold effects on LTD; LFS with Compound 1 at 1 µM yielded EPSPs 48.9 ± 9% of
baseline (n = 5). Compound 2 at 0.1 µM yielded EPSPs 48.2 ± 5.8% of baseline (n = 5). Vehicle control data in C were used for comparisons in D, as the
experiments were performed contemporaneously.
DISCUSSION
Cholesterol oxidation by CYP46A1 is the putative mechanism
responsible for cholesterol clearance from the brain (Russell et al.,
2009). Hence, it is not surprising that CYP46A1 expression is
predominantly localized to the brain (Figure 1). Although mRNA
transcription generally leads to protein synthesis, this is not
always the case, and assumption of a correlation may not be
warranted. Nonetheless, we found that within human and rodent
brain CYP46A1 mRNA and protein expression are similar in
critical brain regions across species, while displaying regional
variability with most abundant expression in striatum and least
abundant in cerebellum (Figures 1A, 2B). Furthermore, 24S-HC
levels, within those two brain regions, appear to mirror CYP46A1
expression (Figure 2C) suggesting a similar enzymatic specific
activity. These observations, supported by previously published
results in CYP46A1 knockout mice (Ramirez et al., 2008; Meljon
et al., 2014), raise the possibility of differential rates of cholesterol
turnover or different mechanisms, beyond CYP46A1, responsible
for maintaining cholesterol homeostasis among different brain
regions. None of the less, having observed an effect on 24S-HC
raises possibility of also impacting cholesterol levels. Although
we did not quantify cholesterol at baseline or in different brain
regions, we do not expect to have had an impact on this endpoint
with manipulations employed in this work. Published reports
indicate no change in global cholesterol level in male CYP46A1
knockout mice or in wildtype mice treated with efavirenz (Petrov
et al., 2020). On the other hand, some viral manipulations of
CYP46A1 result in cholesterol alterations (Ayciriex et al., 2017).
While in both species striatum had the highest CYP46A1
expression and cerebellum the lowest, the magnitude of
CYP46A1 expression in cortex and hippocampus was reversed
between human and mouse (Figures 1A, 2B). This may be, at
least in part, explained by relatively close level of expression
between cortex and hippocampus, the fact that different
techniques were utilized to quantify CYP46A1 expression
between the two species or potentially a genuine species
difference. Nonetheless, it appears that CYP46A1 expression is
relatively well-conserved between rodents and humans in brain
areas examined suggesting that rodent species may be suitable
for preclinical studies testing the impact of CYP46A1 inhibitors
in human disease conditions. We note that although rat tissue
was used for testing of the physiological impact of inhibitors
(Figures 5B–D), rat vs. mouse CYP46A1 protein sequence is
98.6% identical and 99.6% similar (EMBOSS Needle alignment)
at the amino acid level, and 24S-HC levels previously measured
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FIGURE 6 | Systemic treatment with CYP46A1 inhibitor decreased central and peripheral 24S-HC. Mouse PK after single systemic administration of 30 mg/kg of
compound 1 (A). Significant plasma 24S-HC reduction observed 8 h after compound 1 administration (B). Brain 24S-HC reduction observed between 4 and 16 h
after CYP46A1 inhibitor treatment (C). Mouse PK after 3 days of BID administration of compound 1 at 15, 30, and 60 mg/kg doses (D). Significant plasma (E) and
brain (F) 24S-HC reduction observed with every dose. Mouse PK after 3 days of BID administration of compound 2 at 30, 60, and 90 mg/kg doses (G). Significant
plasma (H) and brain (I) 24S-HC reduction observed with every dose. All observations with compound 1 and 2 in the subchronic studies were made 4 h after last
compound administration. Cpd 1, compound 1; Cb, total brain concentration, Cp, total plasma concentration, Cb, u, unbound brain concentration, Cp, u, unbound
plasma concentration. *p < 0.05; ***p < 0.001; ****p < 0.0001.
in rat are similar to those measured in mice in the present work
(Quan et al., 2003).
Brain regions with higher 24S-HC, such as the striatum, cortex
or hippocampus (Figure 2C), may be more affected by treatment
with CYP46A1 inhibitors. To test this hypothesis, we applied two
structurally distinct, potent, efficacious and selective CYP46A1
inhibitors (Figure 3) to mouse striatal and hippocampal slices for
up to 6 h. We expected compounds 1 and 2 to reduce 24S-HC
concentration, but this was not observed (Figure 4). Although
negative results can be difficult to interpret, we do not believe that
degradation of inhibitors is likely, as in vivo experiments showed
good compound exposure for several hours (Figure 6). The result
of Figure 4 could suggest a lack of an effect of the inhibitors
for rodent CYP46A1 enzyme or tissue retention of previously
synthesized 24S-HC.
We reasoned that we could address some of these potential
explanations for lack of 24S-HC reduction with the CYP46A1
inhibitors through brain slice functional assessment. As such,
we utilized hippocampal slice long term depression, a form
of synaptic plasticity that we observed to be susceptible to
CYP46A1 knockout and rescued through exogenous 24S-
HC application (Figure 5A), to test for functional effects of
compounds 1 and 2. Rat hippocampal slice treatment with
voriconazole, a previously reported CYP46A1 inhibitor (Shafaati
et al., 2010), and compounds 1 and 2 resulted in ablation of
LTD, which was restored through exogenously applied 24S-
HC, with two of the three compounds (Figure 5), consistent
with inhibition of CYP46A1 and lowering of 24S-HC. Through
this CYP46A1 sensitive functional readout we conclude that
the inhibitors are likely impacting 24S-HC levels within half
an hour post administration and are as functional on rodent
CYP46A1 as they are on the human enzyme. Thus, 24S-HC
tissue retention, in the context of the slice media, is likely
responsible for lack of overall 24S-HC change. Our results
also reinforce the previously raised hypothesis that CYP46A1,
and by default 24S-HC, is compartmentalized intracellularly
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(Sodero et al., 2012). We speculate that newly synthesized
24S-HC is important locally for LTD induction, but globally
retained 24S-HC is insufficient. Although local inhibition
of NMDAR function may be the most likely mediator of
LTD inhibition, we found no effect of any of the CYP46A1
inhibitors on isolated NMDAR EPSPs elicited at low frequency
(Supplementary Figure 3). Thus, CYP46A1 mobilization may
depend on sustained NMDAR stimulation required for plasticity
induction (Sodero et al., 2012). Furthermore, despite the in vitro
selectivity of compound 2 (Supplementary Tables 1–3), it is
possible we encountered an off target mediated effect on LTD
(Supplementary Table 1). A difference between compound 1
and compound 2 could arise from the substantial structural
differences (Figure 1A). Cultivating inhibitors from differing
structural scaffolds could be beneficial in the search for a clinically
useful compound.
Several possibilities exist for an LTD, but not an LTP effect
in hippocampal slices from CYP46A1 KO mice (Figure 5A;
Sun et al., 2016a). It seems unlikely that oxysterol-dependent
LXR effects are involved as changes to plasticity are rapidly
induced by drugs, yet, transcriptional changes typically require
time, and CYP46A1−/− animals actually exhibit counterintuitive
changes to LXR transcriptional targets (Mast et al., 2017). We
have previously shown that CYP46A1−/− hippocampal neurons
exhibit reduced NMDAR tone (Sun et al., 2016a). Although
24S-HC NMDAR effects would be expected to modulate both
LTP and LTD, LTD could exhibit higher sensitivity than LTP
to small changes to NMDAR function triggered by changes in
local 24S-HC concentration. Another possibility is that local
NMDAR-induced changes to cholesterol at synapses, induced by
activity-driven CYP46A1 catalysis (Sodero et al., 2012), could
be important to LTD but not LTP. CYP46A1−/− mice do
not exhibit changes to brain bulk cholesterol concentration
(Lund et al., 2003; Meljon et al., 2014), but local changes
could be relevant. Finally, given that oxysterol signaling is still
relatively poorly understood, the impact on LTD could involve
an undescribed mechanism.
Systemic acute administration of compound 1 confirmed
that 24S-HC reductions can be achieved (Figures 6B,C) with
a CYP46A1 inhibitor, reinforcing our conclusions from the
hippocampal slice experiments regarding in vivo utility of these
compounds. However, we observed a lag in brain 24S-HC
reduction relative to exposure of the inhibitor as the maximal
compound exposure was observed 2 h after administration
(Figure 6A) yet statistically significant brain 24S-HC reductions
were noted only after 4, 8, and 16 h (Figure 6C). It is hypothesized
that this delay, at least in part, may be a function of very
high brain 24S-HC reservoir, brain clearance rate of 24S-HC
and the rate at which new 24S-HC is synthesized. Furthermore,
larger 24S-HC drawdowns were observed with a subchronic
treatment of the two CYP46A1 inhibitors (Figures 6E,F,H,I)
which enabled compound 1 exposure beyond CYP46A1 in vitro
IC50 for about 8 h a day with the 30 mg/kg dose (Figure 6D).
These results suggest that longer inhibition of CYP46A1, even
when it is not constantly engaged, may lead to larger and more
persistent overall 24S-HC reductions, as reported in the clinic
(Bialer et al., 2018).
CONCLUSION
In conclusion, our data support the hypothesis that inhibition
of the CYP46A1 enzyme impacts brain physiology, most likely
due to lowering 24S-HC levels locally to affect neuronal function.
CYP46A1 inhibitors such as those characterized here could
prove to be clinically relevant treatments in diseases associated
with elevated 24S -HC or NMDAR dysfunction. Furthermore,
our data suggest that rodents could be an adequate species
to study the effects of CYP46A1 inhibition ex vivo and
in vivo.
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